In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors

计算机多靶点分析显示，非选择性β受体阻滞剂可通过ADRB2、ERBB2和NPYR受体发挥其作为乳腺癌辅助治疗关键药物的潜力。